Not Signed In - Ranbaxy Receives FDA Approval To Market Simvastatin 80mg Tablets With 180-Day Exclusivity
Sat, 24 Jun 2006 06:00 AM EST
... Ranbaxy Pharmaceuticals Inc.(RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that the company has received approval from the U.S. Foodand Drug Administration (FDA) to manufacture and market Simvastatin TabletsUSP, 80mg with 180-day exclusivity in the U.S. [click link for full article] ...
Related Topics
- Day Care
- Child Day Care
- Research
- Simvastatin
- Mammography
- Carbinoxamine and Pseudoephedrine Tablets
- Cerivastatin - Withdrawn From The Market
- Vaccine Testing & Approval
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Five a Day Fruits and Vegetables
- Cyanocobalamin Tablets
- Rofecoxib
- Tragacanth
- Chlorpheniramine, Pseudoephedrine and Hydrocodone Tablets
- Tacrolimus ointment
- Guaifenesin and Dextromethorphan
- Neostigmine Tablets
- Haloperidol Tablets
- Thiabendazole Tablets
- Rofecoxib Oral Suspension
email this page
print this page
bookmark this page
feedback on this page
